http://www.thesoulofbiotech.com/2009/06/29/what-are-follow-on-biologics-will-they-really-save-us-billions-of-dollars/ Laughter is the best medicine -- but let's cure cancer anyway. Mon, 27 Jul 2009 16:44:03 +0000 hourly 1 http://wordpress.org/?v=3.3.1 http://www.thesoulofbiotech.com/2009/06/29/what-are-follow-on-biologics-will-they-really-save-us-billions-of-dollars/comment-page-1/#comment-23 Disruptive Women in Health Care » Blog Archive » The future of biotech, follow-on biologics, and BIL:PIL Mon, 27 Jul 2009 16:44:03 +0000 http://www.thesoulofbiotech.com/?p=175#comment-23 [...] interning at the FDA this summer before heading to Harvard Business School). He recently wrote a comprehensive blog post about follow-on biologics, and I had a chance to talk with him about why he’s drawn to health care, biologics issues, [...] [...] interning at the FDA this summer before heading to Harvard Business School). He recently wrote a comprehensive blog post about follow-on biologics, and I had a chance to talk with him about why he’s drawn to health care, biologics issues, [...]

]]> http://www.thesoulofbiotech.com/2009/06/29/what-are-follow-on-biologics-will-they-really-save-us-billions-of-dollars/comment-page-1/#comment-22 hermanek Mon, 06 Jul 2009 13:03:09 +0000 http://www.thesoulofbiotech.com/?p=175#comment-22 The devil is certainly in the details, as you've noted. The more complicated (and costly) the biosimilar approval pathway becomes, the less effective it will be in achieving its intended goal of bringing increased economic competition to the biologic space. But as you wrote, much scientific and manufacturing rigor is necessary to ensure the safety and efficacy of these products. Hopefully Congress will take a thoughtful approach to legislation in this area--much more is at stake than simply dollars and cents. The devil is certainly in the details, as you’ve noted. The more complicated (and costly) the biosimilar approval pathway becomes, the less effective it will be in achieving its intended goal of bringing increased economic competition to the biologic space. But as you wrote, much scientific and manufacturing rigor is necessary to ensure the safety and efficacy of these products. Hopefully Congress will take a thoughtful approach to legislation in this area–much more is at stake than simply dollars and cents.

]]>